(secondQuint)A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies.

 1.

 To evaluate the safety and tolerability of Henatinib, and the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).

 2.

 To determine the pharmacokinetic profile of Henatinib and its metabolites .

 3.

 To assess preliminary antitumor activity .

 4.

 To determine preliminary regimen for phase II study .

.

 A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies@highlight

Henatinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities.

 This study is designed to evaluate the safety and tolerability of Henatinib in patients with Advanced Solid Malignancies